These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 27510721)

  • 1. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
    Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
    Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
    Kim SY; Lee G; Goldie SJ
    BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.
    Clark A; Jauregui B; Griffiths U; Janusz CB; Bolaños-Sierra B; Hajjeh R; Andrus JK; Sanderson C
    Vaccine; 2013 Jul; 31 Suppl 3():C19-29. PubMed ID: 23777686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).
    Wu DB; Chaiyakunapruk N; Chong HY; Beutels P
    Vaccine; 2015 Mar; 33(14):1633-58. PubMed ID: 25681663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
    Mo X; Gai Tobe R; Liu X; Mori R
    Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine.
    Wasserman M; Sings HL; Jones D; Pugh S; Moffatt M; Farkouh R
    Expert Rev Vaccines; 2018 Jan; 17(1):71-78. PubMed ID: 29164952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
    Lara C; De Graeve D; Franco F
    Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
    Giglio N; Micone P; Gentile A
    Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
    Boonacker CW; Broos PH; Sanders EA; Schilder AG; Rovers MM
    Pharmacoeconomics; 2011 Mar; 29(3):199-211. PubMed ID: 21250759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.